Can AI transform life sciences without better data? In this opinion piece, Imperagen CEO Guy Levy-Yurista argues that the biggest challenge is not the models th
Imperagen CEO Guy Levy-Yurista contends that the primary obstacle to AI's advancement in life sciences is not the AI models themselves, but rather the quality and organization of the data they utilize. He advocates for a "closed-loop" system to maximize AI's potential in areas such as biotechnology, drug discovery, and research and development. AI
IMPACT Data quality and structure are critical for AI to deliver value in life sciences, impacting drug discovery and R&D.